

Pulmonary medicine is fundamentally divided into two major categories of ventilatory abnormalities: obstructive lung disease and restrictive lung disease.
The essential distinction is simple:
And the key to telling them apart? It’s not a complex genetic marker or an expensive imaging test. It’s a beautifully simple, old-school engineering test: spirometry.
This is the definitive guide to understanding the restrictive vs. obstructive lung disease split, how we use PFTs to see it, and why it matters so much.
In an obstructive disease, the core issue is increased airway resistance. The pathways—the bronchi and bronchioles—are narrowed, clogged with mucus, or have lost their elastic support, causing them to collapse when the person exhales.
Think of it like trying to empty a full water bottle by squeezing it, but you've only got the cap barely cracked open. It takes a long time, it’s a huge effort, and you probably won't get all the water out.
This is why the hallmark of obstruction is air trapping. Air gets in but can't get out, leading to hyperinflation. The patient is, quite literally, full of old, stale air.
To explore the underlying research, see the Obstructive Lung Disease literature on PubMed.ai.
Air cannot be expelled effectively, resulting in:
The hallmark of obstructive disease is a disproportionate reduction in FEV1 relative to FVC.
The GOLD (Global Initiative for Chronic Obstructive Lung Disease) guideline states:
A post-bronchodilator FEV1/FVC ratio < 0.70 confirms persistent airflow limitation.
A common medical mnemonic CBABE summarizes the major etiologies:
These conditions share the unifying physiological pattern of airflow obstruction despite having different mechanisms and levels of reversibility. To search more examples or related studies, you can explore PubMed.ai’s search engine for high-quality biomedical results.
In a restrictive disease, the airways are often perfectly clear. The "pipes" are fine. The problem is the **lung parenchyma (the tissue itself) or the "bellows" (the chest wall and muscles)**. The lungs have lost their compliance; they've become stiff, scarred, or are being physically restricted from expanding.
Think of trying to inflate one of those tiny, thick-walled water balloons. You can huff and puff, but you can only get a tiny bit of air inside. It simply cannot expand to a normal volume.
Restrictive lung diseases are characterized by reduced lung expansion, which can result from:
The unifying feature is a reduction in lung compliance, making the lungs “stiff” and harder to inflate.
For disease-specific literature, see Restrictive Lung Disease on PubMed.ai.
Unlike obstruction, restrictive disease shows reduced volumes across all parameters, but the FEV1/FVC ratio remains normal or high.
Restriction is confirmed only when TLC is reduced to < 80% of predicted
(American Thoracic Society [ATS] PFT Interpretation Guidelines)
The lungs are essentially sophisticated, self-inflating balloons. Their job is to get air in (ventilation), let oxygen cross into the blood (diffusion), and get CO2 out. Both obstructive and restrictive diseases mess up this simple process, but in completely opposite ways.
| Feature | Obstructive Disease | Restrictive Disease |
|---|---|---|
| Primary Problem | Can't get air out | Can't get air in |
| Mechanism | Airway narrowing / Low recoil | Lung stiffness / Mechanical limitation |
| FEV1 | ↓↓ | ↓ |
| FVC | Normal or ↓ | ↓↓ |
| FEV1/FVC Ratio | Low (< 0.70) | Normal or high (≥ 0.70) |
| TLC | ↑ (> 120%) | ↓ (< 80%) |
| RV | Increased | Decreased |
| Flow–Volume Loop | “Scooped-out” | “Witch’s Hat” |
| Main Diseases | Asthma, COPD, CF | IPF, Obesity, Scoliosis |
The fastest method is to check FEV1/FVC:
Yes. This mixed pattern may occur in:
Interpretation requires full lung volumes and sometimes diffusion capacity (DLCO).
Because spirometry alone (FEV1 and FVC) cannot distinguish restriction from poor effort. A reduced TLC is the definitive marker.
Emphysema, due to hyperinflation and air trapping.
Intrinsic restrictive lung diseases such as pulmonary fibrosis significantly reduce DLCO due to thickened alveolar walls.
To explore more biomedical literature with AI-powered summarization, PICO breakdowns, and intelligent search support, visit:
PubMed.ai helps clinicians, researchers, and medical students rapidly interpret complex pulmonary literature with accuracy and efficiency.
Disclaimer:
The content in this article is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Always consult qualified healthcare professionals regarding any medical condition or treatment decisions.

Have a question about medical research, clinical practice, or evidence-based treatment? Access authoritative, real-time insights: PubMed.ai is an AI-Powered Medical Research Assistant.
Subscribe to our free Newsletter